Drug Trial Radar · NCT06821503
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Apr 11, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.
Conditions
- Advanced Pancreatic Cancer
Interventions
LM-108 injectionDrug
LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.
Penpulimab injectionDrug
Penpulimab injection is a Programmed Cell Death Protein 1 (PD-1) immune checkpoint inhibitor.
Paclitaxel for injection (albumin bound)Drug
Paclitaxel for injection (albumin bound) is a cytotoxic anticancer drug
Gemcitabine hydrochloride for injectionDrug
Gemcitabine hydrochloride for injection is a cell cycle specific anti-tumor drug that can inhibit the growth of tumor cells and belongs to a type of chemotherapy drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: Baseline up to 28 days
- Progression-Free Survival (PFS)Time frame: Up to 48 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing Qeneral Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, Shaanxi, China · Not yet recruiting
The First Affiliated Hospital of Naval Medical University
Shanghai, Shanghai Municipality, China · Not yet recruiting
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.